RCUS
Arcus Biosciences IncNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.99B
P/E Ratio
—
EPS
$-3.17
Beta
0.84
52W High
$28.72
52W Low
$7.91
50-Day MA
$24.14
200-Day MA
$20.69
Dividend Yield
—
Profit Margin
-156.40%
Forward P/E
—
PEG Ratio
—
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Fundamentals
| Revenue (TTM) | $236.00M |
| Gross Profit (TTM) | $-287.00M |
| EBITDA | $-389.00M |
| Operating Margin | -788.00% |
| Return on Equity | -70.00% |
| Return on Assets | -23.10% |
| Revenue/Share (TTM) | $2.07 |
| Book Value | $4.17 |
| Price-to-Book | 5.71 |
| Price-to-Sales (TTM) | 12.68 |
| EV/Revenue | 9.68 |
| EV/EBITDA | 3.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -39.30% |
| Shares Outstanding | $125.77M |
| Float | $89.11M |
| % Insiders | 29.13% |
| % Institutions | 72.41% |
Historical Volatility
HV 10-Day
66.06%
HV 20-Day
56.38%
HV 30-Day
48.83%
HV 60-Day
56.08%
HV Rank
13.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($35.75 target)
9
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026